Canaccord lowered the firm’s price target on Doximity (DOCS) to $58 from $67 and keeps a Hold rating on the shares. The firm said they posted a strong beat and the previously implied 2H FY’26 guidance was essentially maintained which seemed to drive the shares lower. Canaccord said the conservative stance comes from potential DTC advertising and drug pricing changes that have the possibility to drive Pharma management to alter budgets in remaining months of calendar 2025 and plans for calendar 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity’s Earnings Call: Strong Growth and AI Focus
- Doximity price target lowered to $70 from $81 at Evercore ISI
- Balanced Outlook on Doximity: Strong Performance Meets Conservative Guidance
- Doximity Reports Strong Q2 Growth and AI Expansion
- Closing Bell Movers: Expedia up 15%, Affirm up 12% on earnings beats